CJC 1295 no dac + Ipamorelin 5mg/5mg

Name: buy cjc-1295 ipamorelin for sale
Availability: InStock

Price range: $80.00 through $200.00

Quantity

Clear

SKU: N/A Category: Peptides

CJC 1295 No DAC + Ipamorelin 5mg/5mg (Blend Vial) | cjc-1295 ipamorelin for sale

Notice: All products offered on Onyx Labs are strictly intended for laboratory research and analytical testing purposes only. They are not intended for human or animal consumption, diagnostic use, or therapeutic applications.

High-Purity CJC 1295 No DAC + Ipamorelin Blend (10mg Total) | cjc-1295 ipamorelin for sale

The CJC 1295 No DAC + Ipamorelin 5mg/5mg blend combines two powerful, synergistic growth hormone secretagogues into a single, high-purity research vial. Formulated with exact 1:1 ratio precision (5mg CJC-1295 without DAC / Mod GRF 1-29 and 5mg Ipamorelin), this lyophylized research compound allows laboratory investigators to study dual-pathway Growth Hormone Releasing Hormone (GHRH) and Ghrelin Receptor activation.

By binding to separate pituitary receptor sites simultaneously, this co-formulated peptide stack triggers a controlled, pulsatile release of endogenous growth hormone (GH) without causing significant elevations in prolactin or cortisol levels.

Why Source CJC-1295 Ipamorelin For Sale at Onyx Labs?

When sourcing specialized biochemical reagents, batch consistency and verified sequence purity are critical to experimental reproducibility.

Synthesis Verification & Batch Purity

Every batch of our CJC 1295 No DAC and Ipamorelin sequence undergoes rigorous High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) testing to guarantee a purity rating of ≥98%.

Premium Dual-Action Formulation

Instead of handling and reconstituting two separate vials, our pre-blended 5mg/5mg vial simplifies laboratory workflow, reduces contamination risks, and maintains exact stoichiometric ratios for cellular assays and metabolic studies.

Mechanism of Action: How the Blend Functions in Research

The synergistic interaction between CJC 1295 No DAC and Ipamorelin is one of the most widely documented dual-pathway frameworks in growth hormone axis research.

1. CJC 1295 No DAC (Mod GRF 1-29)

Target Pathway: Growth Hormone Releasing Hormone Receptor (GHRHR).
Function: Acts as a synthetic GHRH analog. It mimics the body’s natural signaling mechanism to prompt the anterior pituitary gland to produce and synthesize growth hormone.
Half-Life Profile: Features a short, physiological half-life (~30 minutes), mimicking natural circadian growth hormone spikes rather than continuous elevation.

2. Ipamorelin Diacetate

Target Pathway: Growth Hormone Secretagogue Receptor (GHSR-1a / Ghrelin Receptor).
Function: Selectively signals the pituitary gland to release stored growth hormone.
Selectivity: Unlike older secretagogues (GHRP-2 or GHRP-6), Ipamorelin exhibits exceptional receptor selectivity, minimizing appetite stimulation, cortisol spikes, or unwanted plasma prolactin increases.

Product Specifications & Storage

Parameter	Specification
Product Name	CJC 1295 No DAC + Ipamorelin (Blend)
Sequence Ratio	5mg CJC-1295 No DAC / 5mg Ipamorelin
Total Content	10mg Lyophilized Powder per Vial
Molecular Purity	≥98% (HPLC verified)
Physical State	White Lyophilized Powder
Storage (Unreconstituted)	Store at -20°C (-4°F) for long-term stability; keep dry and away from direct light.
Storage (Reconstituted)	Refrigerate at 2°C – 8°C (36°F – 46°F) and utilize within 30 days.

Frequently Asked Questions: CJC-1295 Ipamorelin For Sale

How is the CJC-1295 Ipamorelin blend shipped?

All peptide vials from Onyx Labs are shipped in protective, climate-conscious packaging to preserve sequence integrity during transit. Once received, vials should be transferred directly to cold storage prior to reconstitution.

How do I access the Certificate of Analysis (CoA) for my batch?

We believe in full laboratory transparency. You can access the HPLC and Mass Spec chromatograms for your specific batch number directly through your MyOnyx account portal or on our dedicated Lab Results page.